Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 PIPELINE ANALYSIS
12.1 CLINICAL TRIALS AND PHASE ANALYSIS
12.2 DRUG THERAPY PIPELINE
12.3 PHASE III CANDIDATES
12.4 PHASE II CANDIDATES
12.5 PHASE I CANDIDATES
12.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
13 REIMBURSEMENT FRAMEWORK
14 OPPUTUNITY MAP ANALYSIS
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY PODUCT TYPE
17.1 OVERVIEW
17.2 ACNE AND ROSACEA DRUGS
17.2.1 TOPICAL RETINOIDS
17.2.2 ORAL RETINOIDS
17.2.3 ANTIBIOTICS
17.2.4 HORMONAL DRUGS
17.2.5 ALPHA AGONISTS (FOR ROSACEA):
17.3 FUNGAL INFECTION DRUGS
17.3.1 AZOLES
17.3.2 ALLYLAMINES
17.3.3 ECHINOCANDINS
17.3.4 OTHER ANTIFUNGALS
17.4 PSORIASIS DRUGS
17.4.1 TOPICAL CORTICOSTEROIDS
17.4.2 VITAMIN D ANALOGUES
17.4.3 TOPICAL RETINOIDS
17.4.4 CALCINEURIN INHIBITORS
17.4.5 BIOLOGICS
17.4.6 OTHERS
17.5 HYPERPIGMENTATION/MELASMA DRUGS
17.5.1 TOPICAL HYDROQUINONE (PRESCRIPTION-STRENGTH)
17.5.2 RETINOIDS
17.5.3 TOPICAL CORTICOSTEROIDS (IN COMBINATION PRODUCTS)
17.5.4 OTHER TOPICAL AGENTS
17.6 SKIN CANCER DRUGS
17.6.1 TOPICAL CHEMOTHERAPEUTICS
17.6.2 TARGETED THERAPY DRUGS
17.6.3 IMMUNE CHECKPOINT INHIBITORS
17.6.4 PHOTODYNAMIC THERAPY AGENTS
17.6.5 OTHERS
17.7 HAIR LOSS AND HAIR REMOVAL DRUGS
17.7.1 HAIR LOSS
17.7.1.1. FINASTERIDE
17.7.1.2. DUTASTERIDE
17.7.1.3. BIMATOPROST
17.7.1.4. OTHERS
17.7.2 HAIR REMOVAL
17.7.2.1. EFLORNITHINE
17.7.2.2. OTHERS
17.8 ANTIAGING AND PHOTO DAMAGE DRUGS
17.8.1 TOPICAL RETINOIDS
17.8.2 ANTIOXIDANTS (PRESCRIPTION STRENGTH)
17.8.3 PEPTIDES (PRESCRIPTION FORMULATIONS)
17.9 DERMATITIS AND SEBORRHEA DRUGS
17.9.1 TOPICAL CORTICOSTEROIDS
17.9.2 CALCINEURIN INHIBITORS
17.9.3 ANTIHISTAMINES
17.9.4 COAL TAR PREPARATIONS
17.9.5 OTHERS
17.1 OTHERS
18 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY DRUG CLASS
18.1 OVERVIEW
18.2 CORTICOSTEROIDS
18.2.1 TOPICAL CORTICOSTEROIDS
18.2.1.1. LOW POTENCY
18.2.1.2. MEDIUM POTENCY
18.2.1.3. HIGH POTENCY
18.2.2 ORAL CORTICOSTEROIDS
18.2.2.1. PREDNISONE
18.2.2.2. DEXAMETHASONE
18.2.2.3. OTHERS
18.2.3 INJECTABLE CORTICOSTEROIDS
18.2.3.1. TRIAMCINOLONE
18.2.3.2. METHYLPREDNISOLONE
18.2.3.3. OTHERS
18.3 RETINOIDS
18.3.1 TOPICAL RETINOIDS
18.3.1.1. TRETINOIN
18.3.1.2. ADAPALENE
18.3.1.3. TAZAROTENE
18.3.2 ORAL RETINOIDS
18.3.2.1. ISOTRETINOIN
18.3.2.2. ACITRETIN
18.3.2.3. OTHERS
18.4 ANTIBIOTICS
18.4.1 TOPICAL ANTIBIOTICS
18.4.1.1. CLINDAMYCIN
18.4.1.2. MUPIROCIN
18.4.1.3. ERYTHROMYCIN
18.4.2 ORAL ANTIBIOTICS
18.4.2.1. DOXYCYCLINE
18.4.2.2. MINOCYCLINE
18.4.2.3. OTHERS
18.5 ANTIFUNGALS
18.5.1 TOPICAL ANTIFUNGALS
18.5.1.1. CLOTRIMAZOLE
18.5.1.2. KETOCONAZOLE
18.5.1.3. MICONAZOLE
18.5.2 ORAL ANTIFUNGALS
18.5.2.1. FLUCONAZOLE
18.5.2.2. ITRACONAZOLE
18.5.2.3. TERBINAFINE
18.6 IMMUNOSUPPRESSANTS
18.6.1 TOPICAL IMMUNOSUPPRESSANTS
18.6.1.1. TACROLIMUS
18.6.1.2. PIMECROLIMUS
18.6.1.3. OTHERS
18.6.2 ORAL IMMUNOSUPPRESSANTS
18.6.2.1. CYCLOSPORINE
18.6.2.2. METHOTREXATE
18.6.2.3. AZATHIOPRINE
18.7 BIOLOGICS
18.7.1 MONOCLONAL ANTIBODIES
18.7.1.1. TNF INHIBITORS
18.7.1.2. IL-12/23 INHIBITORS
18.7.1.3. IL-17 INHIBITORS
18.7.2 FUSION PROTEINS
18.7.3 CYTOKINE INHIBITORS
18.8 OTHERS
19 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY INDICATION
19.1 OVERVIEW
19.2 ACNE
19.2.1 MILD ACNE
19.2.2 MODERATE ACNE
19.2.3 SEVERE ACNE
19.3 PSORIASIS
19.3.1 PLAQUE PSORIASIS
19.3.2 GUTTATE PSORIASIS
19.3.3 PUSTULAR PSORIASIS
19.4 ECZEMA
19.4.1 ATOPIC DERMATITIS
19.4.2 CONTACT DERMATITIS
19.4.3 SEBORRHEIC DERMATITIS
19.5 ROSACEA
19.5.1 ERYTHEMATOTELANGIECTATIC ROSACEA
19.5.2 PAPULOPUSTULAR ROSACEA
19.5.3 PHYMATOUS ROSACEA
19.6 FUNGAL SKIN INFECTIONS
19.6.1 RINGWORM
19.6.2 CANDIDIASIS
19.7 BACTERIAL SKIN INFECTIONS
19.7.1 IMPETIGO
19.7.2 CELLULITIS
19.7.3 FOLLICULITIS
19.8 ALOPECIA
19.8.1 ANDROGENETIC ALOPECIA
19.8.2 ALOPECIA AREATA
19.9 HYPERPIGMENTATION
19.9.1 MELASMA
19.9.2 POST-INFLAMMATORY HYPERPIGMENTATION
19.1 VIRAL SKIN INFECTIONS
19.10.1 WARTS
19.10.2 HERPES SIMPLEX
19.10.3 MOLLUSCUM CONTAGIOSUM
19.11 OTHERS
20 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
20.1 OVERVIEW
20.2 TOPICAL
20.2.1 CREAMS
20.2.2 OINTMENTS
20.2.3 GELS
20.2.4 LOTIONS
20.2.5 FOAMS
20.3 ORAL
20.3.1 TABLETS
20.3.2 CAPSULES
20.3.3 LIQUID FORMULATIONS
20.4 INJECTABLE
20.4.1 INTRAVENOUS
20.4.2 SUBCUTANEOUS
20.4.3 INTRAMUSCULAR
21 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY DRUG TYOE
21.1 OVERVIEW
21.2 BRANDED
21.3 GENERIC
22 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY GENDER
22.1 OVERVIEW
22.2 MALE
22.3 FEMALE
23 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY AGE GROUP
23.1 OVERVIEW
23.2 PEDIATRIC
23.3 ADULT
23.4 GERIATRIC
24 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
24.1 OVERVIEW
24.2 HOSPITAL PHARMACIES
24.3 RETAIL PHARMACIES
24.4 ONLINE PHARMACIES
24.5 OTHERS
25 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY GEOGRAPHY
26 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, BY GEOGRAPHY
GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1 NORTH AMERICA
26.1.1 U.S.
26.1.2 CANADA
26.1.3 MEXICO
26.2 EUROPE
26.2.1 GERMANY
26.2.2 FRANCE
26.2.3 U.K.
26.2.4 ITALY
26.2.5 SPAIN
26.2.6 RUSSIA
26.2.7 TURKEY
26.2.8 BELGIUM
26.2.9 NETHERLANDS
26.2.10 SWITZERLAND
26.2.11 REST OF EUROPE
26.3 ASIA-PACIFIC
26.3.1 JAPAN
26.3.2 CHINA
26.3.3 SOUTH KOREA
26.3.4 INDIA
26.3.5 AUSTRALIA
26.3.6 SINGAPORE
26.3.7 THAILAND
26.3.8 MALAYSIA
26.3.9 INDONESIA
26.3.10 PHILIPPINES
26.3.11 REST OF ASIA-PACIFIC
26.4 SOUTH AMERICA
26.4.1 BRAZIL
26.4.2 ARGENTINA
26.4.3 PERU
26.4.4 CHILE
26.4.5 COLOMBIA
26.4.6 VENEZUELA
26.4.7 REST OF SOUTH AMERICA
26.5 MIDDLE EAST AND AFRICA
26.5.1 SOUTH AFRICA
26.5.2 SAUDI ARABIA
26.5.3 UAE
26.5.4 EGYPT
26.5.5 ISRAEL
26.5.6 REST OF MIDDLE EAST AND AFRICA
26.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, COMPANY LANDSCAPE
27.1 COMPANY SHARE ANALYSIS: GLOBAL
27.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
27.3 COMPANY SHARE ANALYSIS: EUROPE
27.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
27.5 MERGERS & ACQUISITIONS
27.6 NEW PRODUCT DEVELOPMENT & APPROVALS
27.7 EXPANSIONS
27.8 REGULATORY CHANGES
27.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
28 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS
29 GLOBAL PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET, COMPANY PROFILE
29.1 JOHNSON & JOHNSON
29.1.1 COMPANY OVERVIEW
29.1.2 REVENUE ANALYSIS
29.1.3 GEOGRAPHIC PRESENCE
29.1.4 PRODUCT PORTFOLIO
29.1.5 RECENT DEVELOPEMENTS
29.2 ABBVIE INC.
29.2.1 COMPANY OVERVIEW
29.2.2 REVENUE ANALYSIS
29.2.3 GEOGRAPHIC PRESENCE
29.2.4 PRODUCT PORTFOLIO
29.2.5 RECENT DEVELOPEMENTS
29.3 NOVARTIS INTERNATIONAL AG
29.3.1 COMPANY OVERVIEW
29.3.2 REVENUE ANALYSIS
29.3.3 GEOGRAPHIC PRESENCE
29.3.4 PRODUCT PORTFOLIO
29.3.5 RECENT DEVELOPEMENTS
29.4 PFIZER INC.
29.4.1 COMPANY OVERVIEW
29.4.2 REVENUE ANALYSIS
29.4.3 GEOGRAPHIC PRESENCE
29.4.4 PRODUCT PORTFOLIO
29.4.5 RECENT DEVELOPEMENTS
29.5 ROCHE HOLDING AG
29.5.1 COMPANY OVERVIEW
29.5.2 REVENUE ANALYSIS
29.5.3 GEOGRAPHIC PRESENCE
29.5.4 PRODUCT PORTFOLIO
29.5.5 RECENT DEVELOPEMENTS
29.6 SANOFI S.A.
29.6.1 COMPANY OVERVIEW
29.6.2 REVENUE ANALYSIS
29.6.3 GEOGRAPHIC PRESENCE
29.6.4 PRODUCT PORTFOLIO
29.6.5 RECENT DEVELOPEMENTS
29.7 L'ORÉAL S.A.
29.7.1 COMPANY OVERVIEW
29.7.2 REVENUE ANALYSIS
29.7.3 GEOGRAPHIC PRESENCE
29.7.4 PRODUCT PORTFOLIO
29.7.5 RECENT DEVELOPEMENTS
29.8 GLAXOSMITHKLINE PLC
29.8.1 COMPANY OVERVIEW
29.8.2 REVENUE ANALYSIS
29.8.3 GEOGRAPHIC PRESENCE
29.8.4 PRODUCT PORTFOLIO
29.8.5 RECENT DEVELOPEMENTS
29.9 MERCK & CO., INC.
29.9.1 COMPANY OVERVIEW
29.9.2 REVENUE ANALYSIS
29.9.3 GEOGRAPHIC PRESENCE
29.9.4 PRODUCT PORTFOLIO
29.9.5 RECENT DEVELOPEMENTS
29.1 ELI LILLY AND COMPANY
29.10.1 COMPANY OVERVIEW
29.10.2 REVENUE ANALYSIS
29.10.3 GEOGRAPHIC PRESENCE
29.10.4 PRODUCT PORTFOLIO
29.10.5 RECENT DEVELOPEMENTS
29.11 BAYER AG
29.11.1 COMPANY OVERVIEW
29.11.2 REVENUE ANALYSIS
29.11.3 GEOGRAPHIC PRESENCE
29.11.4 PRODUCT PORTFOLIO
29.11.5 RECENT DEVELOPEMENTS
29.12 AMGEN INC.
29.12.1 COMPANY OVERVIEW
29.12.2 REVENUE ANALYSIS
29.12.3 GEOGRAPHIC PRESENCE
29.12.4 PRODUCT PORTFOLIO
29.12.5 RECENT DEVELOPEMENTS
29.13 GALDERMA S.A.
29.13.1 COMPANY OVERVIEW
29.13.2 REVENUE ANALYSIS
29.13.3 GEOGRAPHIC PRESENCE
29.13.4 PRODUCT PORTFOLIO
29.13.5 RECENT DEVELOPMENTS
29.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
29.14.1 COMPANY OVERVIEW
29.14.2 REVENUE ANALYSIS
29.14.3 GEOGRAPHIC PRESENCE
29.14.4 PRODUCT PORTFOLIO
29.14.5 RECENT DEVELOPMENTS
29.15 CIPLA LTD.
29.15.1 COMPANY OVERVIEW
29.15.2 REVENUE ANALYSIS
29.15.3 GEOGRAPHIC PRESENCE
29.15.4 PRODUCT PORTFOLIO
29.15.5 RECENT DEVELOPMENTS
29.16 ALMIRALL, S.A.
29.16.1 COMPANY OVERVIEW
29.16.2 REVENUE ANALYSIS
29.16.3 GEOGRAPHIC PRESENCE
29.16.4 PRODUCT PORTFOLIO
29.16.5 RECENT DEVELOPMENTS
29.17 LEO PHARMA A/S
29.17.1 COMPANY OVERVIEW
29.17.2 REVENUE ANALYSIS
29.17.3 GEOGRAPHIC PRESENCE
29.17.4 PRODUCT PORTFOLIO
29.17.5 RECENT DEVELOPMENTS
29.18 ASTRAZENECA PLC.
29.18.1 COMPANY OVERVIEW
29.18.2 REVENUE ANALYSIS
29.18.3 GEOGRAPHIC PRESENCE
29.18.4 PRODUCT PORTFOLIO
29.18.5 RECENT DEVELOPMENTS
29.19 NESTLÉ SKIN HEALTH S.A.
29.19.1 COMPANY OVERVIEW
29.19.2 REVENUE ANALYSIS
29.19.3 GEOGRAPHIC PRESENCE
29.19.4 PRODUCT PORTFOLIO
29.19.5 RECENT DEVELOPMENTS
29.2 INCYTE CORPORATION
29.20.1 COMPANY OVERVIEW
29.20.2 REVENUE ANALYSIS
29.20.3 GEOGRAPHIC PRESENCE
29.20.4 PRODUCT PORTFOLIO
29.20.5 RECENT DEVELOPMENTS
29.21 ACLARIS THERAPEUTICS, INC.
29.21.1 COMPANY OVERVIEW
29.21.2 REVENUE ANALYSIS
29.21.3 GEOGRAPHIC PRESENCE
29.21.4 PRODUCT PORTFOLIO
29.21.5 RECENT DEVELOPMENTS
29.22 REVANCE THERAPEUTICS, INC.
29.22.1 COMPANY OVERVIEW
29.22.2 REVENUE ANALYSIS
29.22.3 GEOGRAPHIC PRESENCE
29.22.4 PRODUCT PORTFOLIO
29.22.5 RECENT DEVELOPMENTS
29.23 PERRIGO COMPANY PLC
29.23.1 COMPANY OVERVIEW
29.23.2 REVENUE ANALYSIS
29.23.3 GEOGRAPHIC PRESENCE
29.23.4 PRODUCT PORTFOLIO
29.23.5 RECENT DEVELOPMENTS
29.24 GLENMARK PHARMACEUTICALS LTD.
29.24.1 COMPANY OVERVIEW
29.24.2 REVENUE ANALYSIS
29.24.3 GEOGRAPHIC PRESENCE
29.24.4 PRODUCT PORTFOLIO
29.24.5 RECENT DEVELOPMENTS
29.25 AUROBINDO PHARMA LTD.
29.25.1 COMPANY OVERVIEW
29.25.2 REVENUE ANALYSIS
29.25.3 GEOGRAPHIC PRESENCE
29.25.4 PRODUCT PORTFOLIO
29.25.5 RECENT DEVELOPMENTS
29.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.
29.26.1 COMPANY OVERVIEW
29.26.2 REVENUE ANALYSIS
29.26.3 GEOGRAPHIC PRESENCE
29.26.4 PRODUCT PORTFOLIO
29.26.5 RECENT DEVELOPMENTS
29.27 HIKMA PHARMACEUTICALS PLC
29.27.1 COMPANY OVERVIEW
29.27.2 REVENUE ANALYSIS
29.27.3 GEOGRAPHIC PRESENCE
29.27.4 PRODUCT PORTFOLIO
29.27.5 RECENT DEVELOPMENTS
29.28 GLENMARK PHARMACEUTICALS INC.
29.28.1 COMPANY OVERVIEW
29.28.2 REVENUE ANALYSIS
29.28.3 GEOGRAPHIC PRESENCE
29.28.4 PRODUCT PORTFOLIO
29.28.5 RECENT DEVELOPMENTS
29.29 ENDO INTERNATIONAL PLC
29.29.1 COMPANY OVERVIEW
29.29.2 REVENUE ANALYSIS
29.29.3 GEOGRAPHIC PRESENCE
29.29.4 PRODUCT PORTFOLIO
29.29.5 RECENT DEVELOPMENTS
29.3 DERMAVANT SCIENCES, INC.
29.30.1 COMPANY OVERVIEW
29.30.2 REVENUE ANALYSIS
29.30.3 GEOGRAPHIC PRESENCE
29.30.4 PRODUCT PORTFOLIO
29.30.5 RECENT DEVELOPMENTS
29.31 G&W LABORATORIES, INC.
29.31.1 COMPANY OVERVIEW
29.31.2 REVENUE ANALYSIS
29.31.3 GEOGRAPHIC PRESENCE
29.31.4 PRODUCT PORTFOLIO
29.31.5 RECENT DEVELOPMENTS
30 CONCLUSION
31 QUESTIONNAIRE
32 ABOUT DATA BRIDGE MARKET RESEARCH
